Cancer Therapy News and Research

RSS

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

9 Nov 2011

Protein p97/VCP aids DNA repair like a corkscrew

Human genetic material is constantly at risk of injury from the environment. Possible causes of damage include metabolic processes, chemical substances or ionizing radiation, such as X-radiation.

9 Nov 2011

Semtech to donate $25,000 for new UCLA cancer treatment center

Semtech Corporation, a leading supplier of analog and mixed-signal semiconductors, today announced it will contribute $25,000 to the UCLA Hospital System toward the development of a new treatment center at the Ronald Reagan UCLA Medical Center for teen and young adult cancer patients.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

'Second hit' determines immune response against developing Burkitt's lymphoma

The human c-myc gene encodes a transcription factor (MYC) involved in the regulation of a vast number of other genes - it has been estimated that the transcription of about one in six genes is somehow under the control of MYC.

9 Nov 2011

CWRU to establish umbrella program for integrative oncology

Case Western Reserve University School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin - Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals as national leaders in teaching, research, and patient care in the field of integrative oncology.

8 Nov 2011

DSS VistA Chemotherapy Manager goes live at San Francisco VA Medical Center

DSS, Inc., a leading provider of software development, integration, project management, implementation and support of VistA, today announced that its customized VistA Chemotherapy Manager (VCM) system is now live and in production at the San Francisco VA Medical Center.

7 Nov 2011

Gifts established at Case Western Reserve to educate physicians in integrative oncology

7 Nov 2011

Karolinska Institute researchers discover novel cancer drug target

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target.

7 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011

Women may not receive adequate fertility preservation advice before breast cancer treatment

Women may not receive adequate information on fertility preservation before breast cancer treatment, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

Blocking APE1 enzyme could provide new way to kill cancer cells

BLOCKING a key DNA damage repair enzyme, called APE1, could provide a new way to kill cancer cells containing faulty BRCA genes, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

International research explains why measles virus spreads so quickly

An international collaboration involving Inserm has revealed how the measles virus leaves the body of an infected person to contaminate another individual. The researchers have identified a key receptor, located in the trachea, which allows the virus to spread through the air rapidly from one organism to another. The receptor, nectine-4, is also known to be a biomarker for some cancers.

5 Nov 2011

Measles virus develops a strategy of diabolic elegance

Mayo Clinic researchers have discovered why measles, perhaps the most contagious viral disease in the world, spreads so quickly. The virus emerges in the trachea of its host, provoking a cough that fills the air with particles ready to infect the next host. The findings may also help in the fight against ovarian, breast and lung cancers.

3 Nov 2011

EAU, ESTRO and ESMO to host European conference on urological cancers

The 3rd European Multidisciplinary Meeting on Urological Cancers will kick off this Friday, bringing together representatives of three adjacent fields involved in the management of prostate, bladder, kidney, testicular and penile cancer.

3 Nov 2011

Scientists discover how to starve prostate cancer cells

Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.

3 Nov 2011

New Mayo Clinic social network connects global community of esophageal cancer patients

In 2008, physicians at Mayo Clinic Florida led by Herbert Wolfsen, M.D., were looking for new ways to keep in touch with the large group of esophageal cancer patients cared for by him and other gastroenterologists and surgeons. Telephone calls, faxes and email had worked to create a network of patients but many now wanted interactive and remote access capability to share their experiences and challenges with this serious disease.

1 Nov 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011